Division of Rheumatology, The Pennsylvania State University, College of Medicine, Hershey, PA, USA.
Mallinckrodt Pharmaceuticals, Hazelwood, MO, USA.
J Neuroimmunol. 2021 Apr 15;353:577522. doi: 10.1016/j.jneuroim.2021.577522. Epub 2021 Feb 12.
Repository corticotropin injection (RCI), a complex mixture of adrenocorticotropic hormone (ACTH) analogs and other pituitary peptides, has been found to suppress key aspects of gene expression and cellular function in human B lymphocytes in vitro. The present studies reveal that neither individual POMC peptides (α-MSH, ACTH, ACTH, β-endorphin) nor other related pituitary neuropeptides are sufficient to elicit these effects, even though specific receptors capable of transmitting signals from these peptides are expressed by human B cells. RCI's direct effects on human B cells may require complementary signals from multiple components of the preparation.
促肾上腺皮质激素释放因子(RCI)是一种促肾上腺皮质激素(ACTH)类似物和其他垂体肽的复杂混合物,已被发现可抑制体外人 B 淋巴细胞中关键基因表达和细胞功能的多个方面。本研究表明,即使人 B 细胞表达能够传递这些肽信号的特定受体,单个 POMC 肽(α-MSH、ACTH、ACTH、β-内啡肽)或其他相关垂体神经肽也不足以引起这些效应。RCI 对人 B 细胞的直接影响可能需要制剂的多个成分提供互补信号。